Immunic Stock Fundamentals
| IMUX Stock | USD 0.95 0.04 4.04% |
Immunic fundamentals help investors to digest information that contributes to Immunic's financial success or failures. It also enables traders to predict the movement of Immunic Stock. The fundamental analysis module provides a way to measure Immunic's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Immunic stock.
Immunic |
Immunic Company Current Valuation Analysis
Immunic's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Immunic Current Valuation | 27.67 M |
Most of Immunic's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Immunic is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Immunic has a Current Valuation of 27.67 M. This is 99.81% lower than that of the Biotechnology sector and 99.4% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.83% higher than that of the company.
Immunic Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Immunic's current stock value. Our valuation model uses many indicators to compare Immunic value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Immunic competition to find correlations between indicators driving Immunic's intrinsic value. More Info.Immunic is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Immunic's earnings, one of the primary drivers of an investment's value.Immunic Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immunic's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Immunic could also be used in its relative valuation, which is a method of valuing Immunic by comparing valuation metrics of similar companies.Immunic is currently under evaluation in current valuation category among its peers.
Immunic Fundamentals
| Return On Equity | -2.16 | ||||
| Return On Asset | -0.91 | ||||
| Current Valuation | 27.67 M | ||||
| Shares Outstanding | 90.08 M | ||||
| Shares Owned By Insiders | 1.03 % | ||||
| Shares Owned By Institutions | 64.93 % | ||||
| Number Of Shares Shorted | 5.64 M | ||||
| Price To Earning | (6.65) X | ||||
| Price To Book | 2.08 X | ||||
| EBITDA | (99.11 M) | ||||
| Net Income | (93.61 M) | ||||
| Cash And Equivalents | 72.77 M | ||||
| Cash Per Share | 1.85 X | ||||
| Total Debt | 1.33 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 7.53 X | ||||
| Book Value Per Share | 0.46 X | ||||
| Cash Flow From Operations | (70.83 M) | ||||
| Short Ratio | 6.56 X | ||||
| Earnings Per Share | (1.23) X | ||||
| Price To Earnings To Growth | (0.03) X | ||||
| Target Price | 12.79 | ||||
| Number Of Employees | 85 | ||||
| Beta | 1.88 | ||||
| Market Capitalization | 85.85 M | ||||
| Total Asset | 54.3 M | ||||
| Retained Earnings | (410.89 M) | ||||
| Working Capital | 27.8 M | ||||
| Current Asset | 32.33 M | ||||
| Current Liabilities | 4.73 M | ||||
| Net Asset | 54.3 M |
About Immunic Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Immunic's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immunic using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immunic based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. t and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 65 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Immunic Stock Analysis
When running Immunic's price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.